| 1 |
35425960 | Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. | 2022 Apr 15 |
1 |
| 2 |
35541909 | TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA. | 2022 |
5 |
| 3 |
33397362 | O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma. | 2021 Jan 4 |
3 |
| 4 |
33439503 | Xanthatin synergizes with cisplatin to suppress homologous recombination through JAK2/STAT4/BARD1 axis in human NSCLC cells. | 2021 Feb |
1 |
| 5 |
33536037 | Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin. | 2021 Feb 3 |
1 |
| 6 |
33619228 | Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1. | 2021 Jun |
1 |
| 7 |
33744950 | Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies. | 2021 May 7 |
1 |
| 8 |
33753748 | Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. | 2021 Mar 22 |
1 |
| 9 |
33996534 | The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report. | 2021 |
1 |
| 10 |
34123730 | Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report. | 2021 Sep |
1 |
| 11 |
31639439 | RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence. | 2020 Jan 1 |
4 |
| 12 |
31962039 | Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance. | 2020 Jul |
1 |
| 13 |
32000125 | lncRNA CISAL Inhibits BRCA1 Transcription by Forming a Tertiary Structure at Its Promoter. | 2020 Feb 21 |
2 |
| 14 |
32092597 | Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines | 2020 Jun |
5 |
| 15 |
32097728 | Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. | 2020 May |
1 |
| 16 |
32166000 | Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment. | 2020 Feb 25 |
1 |
| 17 |
32277928 | A lncRNA Decoy Predicts Sensitivity to Cisplatin. | 2020 Apr |
1 |
| 18 |
32405340 | Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line. | 2020 May 5 |
1 |
| 19 |
32407212 | Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast? | 2020 Jul 20 |
1 |
| 20 |
32516091 | Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer. | 2020 Aug 10 |
1 |
| 21 |
32591974 | Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer. | 2020 Dec |
2 |
| 22 |
32816949 | A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. | 2020 Oct 15 |
1 |
| 23 |
33030583 | Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1. | 2020 Nov |
1 |
| 24 |
33074587 | EBV-encoded miRNAs can sensitize nasopharyngeal carcinoma to chemotherapeutic drugs by targeting BRCA1. | 2020 Nov |
1 |
| 25 |
30538112 | Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer. | 2019 Apr 15 |
1 |
| 26 |
30579971 | XPC deficiency leads to centrosome amplification by inhibiting BRCA1 expression upon cisplatin-mediated DNA damage in human bladder cancer. | 2019 Mar 1 |
1 |
| 27 |
30636383 | BRCA1 affects the resistance and stemness of SKOV3-derived ovarian cancer stem cells by regulating autophagy. | 2019 Feb |
1 |
| 28 |
30705591 | RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells. | 2019 |
1 |
| 29 |
30770823 | Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. | 2019 Feb 15 |
1 |
| 30 |
30975989 | Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. | 2019 Apr 11 |
1 |
| 31 |
31273933 | Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. | 2019 Jul |
1 |
| 32 |
31556584 | pH-Sensitive Shell-Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative Breast Cancer. | 2019 Oct 23 |
1 |
| 33 |
31807162 | The inhibitory effects of cisplatin-radiation combination treatment on malignant osteosarcoma MG-63 cells and BRCA1-p53 pathways are more efficient than single treatments. | 2019 Dec |
7 |
| 34 |
29247441 | Predictors of survival for breast cancer patients with a BRCA1 mutation. | 2018 Apr |
1 |
| 35 |
29686231 | Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. | 2018 Apr 23 |
2 |
| 36 |
29905759 | Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. | 2018 Aug 1 |
1 |
| 37 |
30247247 | Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer. | 2018 Oct |
2 |
| 38 |
27130464 | Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus. | 2017 Jan |
1 |
| 39 |
27864890 | Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells. | 2017 May |
1 |
| 40 |
27980104 | The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics. | 2017 Mar |
2 |
| 41 |
28376831 | Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. | 2017 Apr 4 |
1 |
| 42 |
28398198 | Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. | 2017 Apr 11 |
1 |
| 43 |
28427225 | Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia. | 2017 Apr 25 |
1 |
| 44 |
29113350 | BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy. | 2017 Oct 6 |
2 |
| 45 |
29163710 | Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer. | 2017 Dec |
2 |
| 46 |
26801247 | Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. | 2016 Jun 15 |
1 |
| 47 |
26870207 | Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study. | 2016 Jan |
3 |
| 48 |
27186285 | Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer. | 2016 |
6 |
| 49 |
27197267 | The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. | 2016 May 1 |
2 |
| 50 |
27313763 | Successful personalized chemotherapy for metastatic gastric cancer based on quantitative BRCA1 mRNA expression level: A case report. | 2016 Jun |
1 |